AbbVie (ABBV)

• Market cap: $382B
• 1 day: 2.1%
• 5 days: 0.21%
• 1 month: 6.89%
• 3 months: 19.05%
• 6 months: 2.96%
• Year to date: 23.06%
• 1 year: 14.14%
• 5 years: 146.36%
• 10 years: 268.88%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Employees: 55,000

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

54% more call options, than puts

Call options by funds: $3.23B | Put options by funds: $2.09B

16% more repeat investments, than reductions

Existing positions increased: 1,673 | Existing positions reduced: 1,443

1.79% more ownership

Funds ownership: 71.2% [Q1] → 72.99% (+1.79%) [Q2]

7% more first-time investments, than exits

New positions opened: 174 | Existing positions closed: 163

2% less funds holding

Funds holding: 3,762 [Q1] → 3,700 (-62) [Q2]

10% less capital invested

Capital invested by funds: $264B [Q1] → $238B (-$25.9B) [Q2]

38% less funds holding in top 10

Funds holding in top 10: 243 [Q1] → 150 (-93) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $207
• Avg. target: $241
• High target: $270

10 analyst ratings

• positive: 10 100%
• neutral: 0 0%
• negative: 0 0%

Berenberg Luisa Hector	$270	Buy Upgraded	17 Sep 2025
JP Morgan Chris Schott	$235	Overweight Maintained	16 Sep 2025
Cantor Fitzgerald Carter Gould	$245	Overweight Maintained	15 Sep 2025
Wells Fargo Mohit Bansal	$260	Overweight Maintained	12 Sep 2025
BMO Capital Evan David Seigerman	$240	Outperform Maintained	12 Sep 2025